

Full Length Research Paper

The effect of nicotine on the serum level of insulin in adult male Wistar rats

Ebrahim Hosseini

Department of Biology, Islamic Azad University, Marvdasht Branch, Iran. E-mail: ebrahim.hosseini@miau.ac.ir.

Accepted 5 August, 2011

Nicotine is an alkaloid used by millions of people worldwide through cigarette smoking and has adverse effects on every organ and particularly on the endocrine system. Also, millions of humans suffer from diabetes due to either insulin deficiency or insulin resistance. The present study reports the effects of nicotine on the serum level of insulin in adult male Wistar rats. In this empirical research work, we used 50 adult male Wistar rats weighing from 220 to 250 g. The test groups was divided into 3 subgroups containing 10 animals per group received intraperitoneally (IP) either 0.5, 1.0 or 1.5 mg/kg body weight nicotine in 1 ml saline for 5 days and the control group received only the saline through the same route for the same period of time. Twenty four hours after the last injections, blood was drawn from the rat ventricles for serum insulin determination. The results showed that nicotine administration at various dosages enhances the serum level of insulin and an increase in the dosage further elevates the insulin level significantly. It could be concluded from this investigation that nicotine therapy may be beneficial for patients suffering from hypoinsulinism.

Key words: Nicotine, insulin, rats.

INTRODUCTION

Nicotine is an alkaloid extracted from the dry leaves of *Nicotiana tobacum* (Karlsson and Ahrén, 1998) and millions of people worldwide are exposed to it through smoking cigarettes and also via insecticide inhalation. Nicotine consumption results in changes in cardiovascular, neural and endocrine functions through effects on the central and peripheral nervous systems (Benowitz, 1988).

Nicotine increases the plasma levels of ACTH, epinephrine and cortisol hormones, dose dependently (Morgan et al., 2004). Through its effects on the nicotinic receptors of acetylcholine in the pancreatic beta-cells, it increases the segregation and reconstruction of inositol phospholipids and therefore improves the calcium sensitivity of these cells (Hamaguchi et al., 2003). Nicotine consumption effectively releases acetylcholine from the synaptic vesicles in the rat brain. Binding of nicotine to the presynaptic nicotinic receptors of cholinergic neural terminals leads to an increased release of acetylcholine (Yoshikawa et al., 2005). Its peripheral effects are through stimulating acetylcholine nicotinic receptors in parasympathetic and sympatho-adrenal

nervous systems (Arendash et al., 1995) It also affects the liver through epinephrine secretion which leads to an increase in the release of glucose from the liver to the blood (Benowitz, 1986).

Most of acetylcholine postsynaptic functions are mediated by the nicotinic receptors which are ionotropic neurotransmitters. In the presence of an acetylcholine agonist, an increase occurs in the release of epinephrine and norepinephrine from the central part of the adrenals and also insulin from the pancreas (Iguchi, 1986; Benowitz, 1986).

The endocrine part of the pancreatic parasympathetic fibers originates from the dorsal motor vagus in the brain stem and through activating the postganglionic neurons around the pancreas, results in acetylcholine secretion in this gland and stimulates insulin secretion (Gilon and Henquin, 2001; Aleksander et al., 2009; Rashmi and Rodger, 2009).

Insulin hormone with two polypeptide chains and a molecular weight of 5800 dalton, is secreted with other proteins from the pancreatic beta-cells (Draznin and Le Roith, 1994; Rutter and Hill, 2006).

Table 1. Comparison of different amounts of nicotine injected into the peritoneal levels of hormone insulin in the study groups.

Groups	Serum hormone insulin (std. deviation±mean) Pg/ml
Control	181.562 ± 105.201
Witness (1 cc saline)	212.375 ± 146.303
experimental 1 (minimum dose: 0.5 mg/kg)	1434.214 ± 898.149**
experimental 2 (average dose: 1 mg/kg)	1635.312 ± 413.103**
experimental 3 (maximum dose: 1.5 mg/kg)	2473.437 ± 655.030**

** indicate a significant difference in the level ($P \leq 0.01$) with control and witness groups.

Different researchers show that various hormonal and non hormonal factors such as prolactin and growth hormone (Ropero et al., 2002; Brelje et al., 2006), estrogen (Ropero et al., 2002; Soriano et al., 2009), glucocorticoids (Rafacho et al., 2010), glucagon and glucagon-like peptide-I (GLP-1) (Salehi et al., 2010), serotonin (Kim et al., 2010) and glucose (Srinivasan et al., 2005) have adjustment roles on beta cell function and insulin secretion.

Elevation of glucose concentration results in the entry of more glucose into pancreatic beta cells and through an increase in the rate of glycolysis, improves insulin secretion (Bouwens and Rooman, 2010).

Studies show that increased glucose metabolism leads to the production of more ATP in the beta cell cytosol. ATP is the key signal that blocks the ATP dependent potassium channels in the beta cell membrane and induces membrane depolarization of the cell and an increased cytosolic concentration of calcium leads to insulin secretion (Bouwens and Rooman, 2010).

Due to a decrease in insulin secretion caused by the destruction of pancreatic beta cells or the resistance of target tissues to insulin which both lead to diabetes (Bouwens and Rooman, 2010), and based on epidemiologic studies which predict that the number of diabetic patients would increase in the world to a total of 300 million in 2025 (Zimmet et al., 2001), and considering a progressive increase in the number of cigarette smokers, studying the effects of nicotine on the secretion of insulin from the pancreas and the estimation of its serum level becomes of prime importance.

METHODS

In this research we used fifty 90-day old adult male Wistar rats weighing from 220 to 250 g obtained from Razi Vaccine and Serum Institute. The animals were divided into 5 groups of 10 animals each including two control and 3 experimental groups.

Separate cages were used for each group. All the animals received rat chow and water *ad libitum*. The rat room temperature was 22°C with 12 h of darkness and 12 h of light. This research protocol was approved by the ethics committee of Azad University.

In this research, one of the control groups received no treatment and the other one received saline i.p. for 5 consecutive days. The experimental groups received either 0.5, 1 or 1.5 mg/kg nicotine

intraperitoneally for 5 consecutive days and ultimately on the 6th day, the animals were anesthetized mildly with ether and blood were collected from the heart, serum was collected by centrifugation at 5000 rpm. Insulin in the sera of control and experimental groups were estimated by an ELISA method. Data were analysed by SPSS software version 13 using one way ANOVA.

RESULTS

Table 1 shows the effects of various dosages of nicotine on the serum insulin level in male Wistar rats. Nicotine at various dosages increased serum insulin levels significantly and dose dependently.

DISCUSSION

Nicotine is one of the main components of tobacco leaves and millions of consume it through cigarette smoke and also by insecticide inhalation. Nicotine has adverse effects on different organs, particularly on endocrine glands.

In this investigation we studied the effect of the intraperitoneal injection of nicotine on the serum level of insulin in adult male rats. Results show that nicotine stimulates insulin secretion. Studies show that cholinergic agonists such as those of acetylcholine nicotinic receptors enhance the function of sympathoadrenal systems and stimulate the catecholamine hormones secretion leading to hyperglycemia (Ilcol et al., 2002, 2003; Cansev et al., 2007, 2008) and insulin secretion through direct action on the glucose level of pancreatic beta-cells (Ilcol et al., 2007). Nicotine releases acetylcholine from the cholinergic synaptic vesicles effectively and increases the removal of glucose from the liver indirectly through stimulating the muscarinic receptors in the nervous system leading to the stimulation of insulin secretion from pancreas (Uyama et al., 2004). Based on some studies, intraperitoneal injection of choline and phosphocholine as precursors of acetylcholine will result in the stimulation of catecholamine secretion in plasma (Cansev et al., 2007) and cause hyperglycemia (Ilcol et al., 2007) which leads to the stimulation of insulin secretion and its elevation in blood

(Ahrén, 2000; Ilcol et al., 2008).

Binding of nicotine to nicotinic receptors of acetylcholine in the endocrine part of pancreas leads to insulin secretion (Verspohl et al., 1990; Karlsson and Ahrén, 1998). Studies show that administration of choline as a precursor of acetylcholine results in an increase in insulin level in serum through activating nicotinic and muscarinic receptors of acetylcholine (Ilcol et al., 2003; Cansev et al., 2008) thereby increasing the level of acetylcholine agonists in plasma which would have significant effects on the endocrine systems particularly on the secretory function of the endocrine part of the pancreas which produces hormones such as insulin (Gürün et al., 2002; Cavun et al., 2004). Ventro-cerebral administration of choline as a precursor of acetylcholine leads to an increase in insulin secretion into blood upon stimulating the cholinergic-nicotinic and the muscarinic pathways and the use of acetylcholine antagonists such as hexamethonium decreases insulin secretion (Cansev et al., 2008). Acetylcholine and its agonists such as nicotine bind to relevant receptors and increase the production of inositol-1,4,5 triphosphate and release calcium from intracellular calcium stores and reinforce the acute effects of glucose on insulin secretion (Boyd, 1992).

Nicotine and other agonists of acetylcholine stimulate GLP-1 secretion from the ileum which will result in the enhancement of insulin secretion upon increasing intracellular calcium in pancreatic beta cells (Corrigall, 1994).

Investigations reveal that GLP-1 is a glucose and an insulinotropic dependent hormone which stimulates insulin secretion from pancreatic beta cells and has some application in the treatment of diabetes (Herrmann-Rinke, 1995).

GLP-1 is able to cross the blood brain barrier and to stimulate the dorsal motor vagus resulting in an increase in insulin secretion from the pancreas. Also, GLP-1 binds to relevant receptors in the pancreatic beta cells and enhances cAMP production by increasing adenylate cyclase activity, thereby increasing insulin secretion (Sonoda et al., 2008).

Studies show that acetylcholine and its agonist such as nicotine increase the secretion of CRH secretion from hypothalamus and this neuropeptide induces hyperglycemia and stimulates insulin secretion through stimulating ACTH and cortisol secretion (O'Carroll et al., 2004).

Binding of CRH to relevant receptors in the pancreatic beta-cells stimulates insulin secretion through an increase in the intracellular calcium concentration and the activation of protein kinase C (O'Carroll et al., 2004). Acetylcholine agonists such as nicotine stimulate AVP secretion from the hypothalamus and this neuropeptide binds to its receptor in the pancreatic beta cells, increases intracellular calcium concentration, leading to the stimulation of insulin secretion (Rashmi and Rodger, 2009). Agonists of acetylcholine nicotinic receptors

stimulate the secretion of epinephrine and norepinephrine into blood stream (Cansev et al., 2007). These catecholamines also increase glucagon secretion by stimulating pancreatic receptors (Knudtson, 1984; Ahrén and Lundquist 1987; Arslan et al., 1991). Glucagon, also, stimulates insulin secretion through stimulating pancreatic receptors in the beta cells.

Nicotine also stimulates prolactin secretion through its effect on the dorsomedial section of the arched nucleus of hypothalamus. Increased prolactin stimulates insulin secretion by increasing glucose concentration in pancreatic beta-cells (Brelje et al., 2004).

REFERENCES

- Arslan BY, Ulus IH, Savci V, Kiran BK (1991). Effects of intracerebroventricular injected choline on cardiovascular functions and sympathoadrenal activity. *J. Cardiovasc. Pharmacol.*, 17: 814-821.
- Ahrén B, Lundquist I (1987). Alpha-adrenoceptor blockade by phentolamine inhibits beta-adrenergically and cholinergically induced glucagon secretion in the mouse. *Horm. Metab. Res.*, 19: 600-603.
- Arendash GW, Sanberg PR, Sengstock GJ (1995). Nicotine enhances the learning and memory of aged rats. *Pharmacol. Biochem. Behav.*, 52: 517-523.
- Aleksander S, Jacek K, Elzbieta N, Tadeusz K (2009). Autonomic Innervation of Pancreas in Egyptian Spiny Mouse (*Acomys cahirinus*, Desmarest). *Acta. Vet. Brno.*, 78: 557-561.
- Ahrén B (2000). Autonomic regulation of islet hormone secretion-implications for health and disease. *Diabetologia*. 43:393-410.
- Benowitz NL (1986). Clinical pharmacology of nicotine. *Annu. Rev. Med.*, 37: 21-32.
- Benowitz NL (1988). Drug therapy. Pharmacologic aspects of cigarette smoking and nicotine addiction. *N Engl. J. Med.*, 319: 1318-1330.
- Brelje TC, Stout LE, Bhagoo NV, Sorenson RL (2004). Distinctive roles for prolactin and growth hormone in the activation of signal transducer and activator of transcription 5 in pancreatic islets of langerhans. *Endocrinology*. 145: 4162-4175.
- Bouwens L, Rooman I (2005). Regulation of pancreatic beta-cell mass. *Physiol. Rev.*, 85: 1255-1270.
- Boyd AE 3rd (1992). The role of ion channels in insulin secretion. *J. Cell. Biochem.*, 48: 235-241.
- Corrigall WA, Coen KM, Adamson KL (1994). Self-administered nicotine activates the mesolimbic dopamine system through the ventral tegmental area. *Brain. Res.*, 653: 278-284.
- Choi K, Kim Y (2010). Molecular Mechanism of Insulin Resistance in Obesity and Type 2 Diabetes. *Korean. J. Int. Med.*, 25: 119-129
- Cansev M, Yilmaz MS, Ilcol YO, Hamurtekin E, Ulus IH (2007). Cardiovascular effects of CDP-choline and its metabolites: involvement of peripheral autonomic nervous system. *Eur. J. Pharmacol.*, 577: 129-142.
- Cansev M, Ilcol YO, Yilmaz MS, Hamurtekin E, Ulus IH (2008). Peripheral administration of CDP-choline, phosphocholine or choline increases plasma adrenaline and noradrenaline concentrations. *Auton. Autacoid. Pharmacol.*, 28: 41-58.
- Cansev M, Ilcol YO, Yilmaz MS, Hamurtekin E, Ulus IH (2008). Choline, CDP-choline or phosphocholine increases plasma glucagon in rats: involvement of the peripheral autonomic nervous system. *Eur. J. Pharmacol.*, 589: 315-322.
- Cavun S, Savci V, Ulus IH (2004). Centrally injected CDP-choline increases plasma vasopressin levels by central cholinergic activation. *Fundam. Clin. Pharmacol.*, 18: 71-77.
- Draznin B, Le Roith D (1994). *Molecular Biology of Diabetes*. Human Press, p. 204.
- Gilon P, Henquin JC (2001). Mechanisms and physiological significance of the cholinergic control of pancreatic beta-cell function. *Endocr. Rev.*, 22: 565-604.

- Gilon P, Henquin JC (2001). Mechanisms and physiological significance of the cholinergic control of pancreatic beta-cell function. *Endocr. Rev.*, 22: 565-604.
- Gürün MS, Ilçöl YO, Taga Y, Ulus IH (2002). Hyperglycemia induced by intracerebroventricular choline: involvement of the sympatho-adrenal system. *Eur. J. Pharmacol.*, 438: 197-205.
- Herrmann-Rinke C, Vöge A, Hess M, Göke B (1995). Regulation of glucagon-like peptide-1 secretion from rat ileum by neurotransmitters and peptides. *J. Endocrinol.*, 147: 25-31.
- Hamaguchi K, Utsunomiya N, Takaki R, Yoshimatsu H, Sakata T (2003). Cellular interaction between mouse pancreatic alpha-cell and beta-cell lines: possible contact-dependent inhibition of insulin secretion. *Exp. Biol. Med.*, 228: 1227-1233.
- Iguchi A, Gotoh M, Matsunaga H, Yatomi A, Honmura A, Yanase M, Sakamoto N (1986). Mechanism of central hyperglycemic effect of cholinergic agonists in fasted rats. *Am. J. Physiol.*, 251: 1-7.
- Ilcol YO, Gurun MS, Taga Y, Ulus IH (2002). Intraperitoneal administration of choline increases serum glucose in rat: involvement of the sympathoadrenal system. *Horm. Metab. Res.*, 34: 341-347.
- Ilcol YO, Cansev M, Yilmaz MS, Hamurtekin E, Ulus IH (2007). Intraperitoneal administration of CDP-choline and its cholinergic and pyrimidineric metabolites induce hyperglycemia in rats: involvement of the sympathoadrenal system. *Arch. Physiol. Biochem.*, 113: 186-201.
- Ilcol YO, Gurun MS, Taga Y, Ulus IH (2003). Choline increases serum insulin in rat when injected intraperitoneally and augments basal and stimulated acetylcholine release from the rat minced pancreas *in vitro*. *Eur. J. Biochem.*, 270: 991-999.
- Ilcol YO, Cansev M, Yilmaz MS, Hamurtekin E, Ulus IH (2008). Peripheral administration of CDP-choline and its cholinergic metabolites increases serum insulin: muscarinic and nicotinic acetylcholine receptors are both involved in their actions. *Neurosci. Lett.*, 431: 71-76.
- Karlsson S, Åhrén B (1998). Insulin and glucagon secretion by ganglionic nicotinic activation in adrenalectomized mice. *Eur. J. Pharmacol.*, 342: 291-295.
- Knudtzon J (1984). Adrenergic effects on plasma levels of glucagon, insulin, glucose and free fatty acids in rabbits-influences of selective blocking drugs. *Acta. Physiol. Scand.*, 120: 353-361.
- Karlsson S (1998). Åhrén B. Insulin and glucagon secretion by ganglionic nicotinic activation in adrenalectomized mice. *Eur. J. Pharmacol.*, 342: 291-295.
- Kim H, Toyofuku Y, Lynn FC, Chak E, Uchida T, Mizukami HI, Fujitani Y, Kawamori R, Miyatsuka T, Kosaka Y, Yang K, Honig G, Marieke van der Hart, Kishimoto N, Wang J, Yagihashi S, Tecott LH, Watada H, German MS (2010). Serotonin Regulates Pancreatic β -Cell Mass during Pregnancy. *Nat. Med.*, 16: 804-808.
- Morgan TM, Crawford L, Stoller A, Toth D, Yeo KT, Baron JA (2004). Acute effects of nicotine on serum glucose insulin growth hormone and cortisol in healthy smokers. *Metabolism*, 53: 578-582.
- O'Carroll AM, Howell GM, Roberts EM, Lolait SJ (2008). Vasopressin potentiates corticotropin-releasing hormone-induced insulin release from mouse pancreatic beta-cells. *J. Endocrinol.*, 197: 231-239.
- Rashmi C, Rodger AL (2009). Neural and Hormonal Regulation of Pancreatic Secretion. *Curr Opin Gastroenterol.*, 25: 441-446.
- Rutter GA, Hill EV (2006). Insulin vesicle release: walk, kiss, pause then run. *Physiology (Bethesda)*. 21: 189-196.
- Ropero AB, Soria B, Nadal A (2002). A nonclassical estrogen membrane receptor triggers rapid differential actions in the endocrine pancreas. *Mol. Endocrinol.*, 16: 497-505.
- Rafacho A, Marroquí L, Taboga SR, Abrantes JL, Silveira LR, Boschero AC, Carneiro EM, Bosqueiro JR, Nadal A, Quesada I (2010). Glucocorticoids *in vivo* induce both insulin hypersecretion and enhanced glucose sensitivity of stimulus-secretion coupling in isolated rat islets. *Endocrinology*, 151: 85-95.
- Soriano S, Ropero AB, Alonso-Magdalena P, Ripoll C, Quesada I, Gassner B, Kuhn M, Gustafsson JA, Nadal A (2009). Rapid regulation of K (ATP) channel activity by 17 β -estradiol in pancreatic β -cells involves the estrogen receptor β and the atrial natriuretic peptide receptor. *Mol. Endocrinol.*, 23: 1973-1982.
- Salehi M, Aulinger B, Prigeon RL, D'Alessio DA (2010). Effect of endogenous GLP-1 on insulin secretion in type 2 diabetes. *Diabetes*. 59: 1330-1337.
- Srinivasan S, Bernal-Mizrachi E, Ohsugi M, Permutt MA (2002). Glucose promotes pancreatic islet beta-cell survival through a PI 3-kinase/Akt-signaling pathway. *Am. J. Physiol. Endocrinol. Metab.*, 283: 84-93.
- Sonoda N, Imamura T, Yoshizaki T, Babendure JL, Lu JC, Olefsky JM (2008). Beta-Arrestin-1 mediates glucagon-like peptide-1 signaling to insulin secretion in cultured pancreatic beta cells. *Proc. Natl. Acad. Sci. U S A.*, 105: 6614-6619.
- Uyama N, Geerts A, Reynaert H (2004). Neural connections between the hypothalamus and the liver. *Anat. Rec. A. Discov. Mol. Cell. Evol. Biol.*, 280: 808-820.
- Verspohl EJ, Tacke R, Mutschler E, Lambrecht G (1990). Muscarinic receptor subtypes in rat pancreatic islets: binding and functional studies. *Eur. J. Pharmacol.*, 178: 303-311.
- Yoshikawa H, Hellström-Lindahl E, Grill V (2005). Evidence for functional nicotinic receptors on pancreatic beta cells. *Metabolism*, 54: 247-254.
- Zimmet P, Alberti KG, Shaw J (2001). Global and societal implications of the diabetes epidemic. *Diabetologia*, 44: 782-787.